Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094059
Filing Date
2024-08-08
Accepted
2024-08-08 16:24:18
Documents
59
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tnya-20240630.htm   iXBRL 10-Q 1985066
2 EX-10.1 tnya-ex10_1.htm EX-10.1 54410
3 EX-31.1 tnya-ex31_1.htm EX-31.1 20692
4 EX-31.2 tnya-ex31_2.htm EX-31.2 20798
5 EX-32.1 tnya-ex32_1.htm EX-32.1 13020
  Complete submission text file 0000950170-24-094059.txt   6909142

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20240630.xsd EX-101.SCH 900709
62 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20240630_htm.xml XML 1016774
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40656 | Film No.: 241188803
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)